Clinical Trial Update: A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 study evaluating HGS1029 (AEG40826-2HCl) in patients with advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• HGS1029 (AEG40826-2HCl) (AEG40826-2HCl)

Snippet

Sponsor: Human Genome Sciences Inc. | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED